RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Deals
Like Takeda's US$6 Billion acquisition announced yesterday of a Phase 2/Phase 3 ready psoriasis drug, ONCY' pelareorep is also a "Phase 3 ready" drug that is can potentially achieve "breakthrough" designation and an accelerated approval status that would result in immediate marketing approval followed-up with a post-marketing confirmatory trial for final FDA/EMA approval.
Takeda's US$6 Billion acquisition of Nimbus Lakshimi follows what is seen as the increased scrutiny from the US Federal Trade Commission (FTC) around larger deals which is signalling that 2022/2023 will be a time of bolt-on transactions in the $5 to $15 billion range as Big Pharma companies seek to acquire small to medium size enterprises to make up for revenues lost to generic competition in the remainder of the decade.
As with the Takeda's acquisition of Nimbus Lakshimi expect to see Big Pharma picking up earlier-late stage companies to try and fill the pipeline gaps that are likely to start in 2024.